Dräger adopts Masimo pulse oximetry platform

21 November 2006

London, UK. Dräger Medical AG & Co. KG  will integrate the Masimo Rainbow SET platform as its principal pulse oximetry patient monitoring technology.

The Rainbow SET platform offers Masimo SET read-through motion and low perfusion pulse oximetry plus upgradeability to add other parameters in the future. Upgrades are available today for carboxyhemoglobin (carbon monoxide) and methemoglobin and others are planned for the future. Dräger Medical will be incorporating Masimo Rainbow SET into major acute care products.

For future product developments, Dräger Medical will replace its Oxisure+ oximetry with Masimo technology. This agreement between Dräger Medical and Masimo also constitutes a release of each other from any potential patent infringement claims relating to pulse oximetry.

Dr. Wolfgang Reim, President and CEO of Dräger Medical stated, "We are excited to be able to extend our existing relationship and again be one of the first companies to provide our customers with the latest advancements in noninvasive patient monitoring technology. Masimo SET is clearly the gold standard in motion tolerant pulse oximetry technology and with its new Rainbow Technology, Masimo extends the reach of its technology to new important parameters. Dräger Medical and Masimo have enjoyed a great partnership that we are very happy to expand.”

Joe E. Kiani, Chairman and CEO of Masimo stated, "We greatly value our relationship with Dräger Medical and are happy to be expanding our relationship with this new agreement. Dräger Medical’s leadership in patient monitoring and therapeutic systems is well recognized by numerous customers around the world. We are delighted to see Dräger Medical taking Masimo Rainbow SET to its customers, and thereby improving care of millions of patients."

To top